Malignant astrocytoma, the most prevalent primary brain tumor, is resistant to all known therapies and frequently harbors mutations that inactivate p53 and activate Ras signaling. We have generated mouse strains that lack p53 and harbor a conditional allele of the NF1 tumor suppressor that negatively regulates Ras signaling. The mice develop malignant astrocytomas with complete penetrance. The majority of tumors display characteristics of glioblastoma multiforme with concomitant alteration of signaling pathways previously described in the human counterparts of this neoplasm. We find that the sequence of tumor suppressor inactivation influences tumorigenicity and that earliest evidence of tumor formation localizes to regions of the brain that contain a multipotent stem cell population capable of in vivo differentiation into neurons and glia.
Introduction
grade astrocytomas are loss of p53 and elevated expression of platelet-derived growth factor (PDGF) and its receptor tyrosine Astrocytomas, composed predominantly of astrocyte-like cells, kinase (RTK), PDGFR (Guha et al., 1995; Hermanson et al. , are the most common neoplasm in the central nervous system 1992; Nister et al., 1988) . These observations suggest that (CNS) (Kleihues and Cavenee, 2000) . According to the World these pathways may participate in the initiation of astrocytoma. Health Organization (WHO) grading system, grade II-IV astroIndividuals afflicted with neurofibromatosis type 1 (NF1) are cytomas (collectively called malignant astrocytoma) are biolopredisposed to malignant astrocytoma in the brain with a gically malignant and diffusely infiltrate the brain. Grade IV greater than 5-fold increased incidence throughout their lives astrocytoma, or glioblastoma multiforme (GBM), is one of the (Rasmussen et al., 2001) . The NF1 tumor suppressor product most aggressive human cancers, with a median survival of less neurofibromin is a functional Ras GTPase-activating protein than 1 year. Unfortunately, this prognosis has not changed sig-(GAP) (Cichowski and Jacks, 2001; ). nificantly over the past two decades, despite advances in neuThus, loss of neurofibromin results in abnormal activation of rosurgery, radiation, and chemotherapy (Holland, 2001 ; Maher Ras, a major mediator of RTK signaling. et al., 2001; .
Heterozygous mice carrying germline null mutations in both There are two subtypes of GBMs. Primary GBMs arise rapp53 and NF1 on the same chromosome (termed cisNF1/p53 idly or de novo without any evidence of prior clinical disease, mice) develop low-to intermediate-grade astrocytomas, with whereas secondary GBMs derive from preexisting low-grade up to 75% penetrance depending on the genetic background lesions after long latency ranging from 5 to 10 years (Kleihues (Reilly et al., 2000 , 2004 . We reasoned that the increased inciand Cavenee, 2000; Maher et al., 2001) . Human genetic studies indicate that two frequent molecular characteristics of lowdence of astrocytoma in NF1 patients might indicate a con-tween embryonic day 10.5 (E10.5) and E12.5, Cre-mediated recombination, as revealed by LacZ expression, was evident in discrete neuroectodermal regions of the forebrain and hindbrain and in trigeminal ganglia (see Figures S1A-S1F in the Supplemental Data available with this article online). Consistent with previous reports (Malatesta et al., 2003; Zhuo et al., 2001) , the consequence of early ventricular Cre expression in neural progenitor cells is that, at birth (P0.5), most cortical and hippocampal neurons express the LacZ reporter gene (Figures S1G-S1I). Thus, early onset of the human GFAP promoter in neural progenitor cells leads to Cre-mediated recombination in early CNS cells as well as their progeny, including adult neural stem/progenitor cells in the SVZ (Merkle et al., 2004; Tramontin et al., 2003) and neurons, astrocytes, and oligodendrocytes (Malatesta et al., 2003; Zhuo et al., 2001 ;hGFAP-cre+) mice lack p53 in the germline and NF1 function in CNS cells as a consequence of hGFAP-cre-mediated recombination in developing neural pro- genitor cells and mature astrocytes (Malatesta et al., 2003;  The green color is used to label the normal alleles, including the wild-type allele (+) and the floxed allele (x1); the red color is used to label the null Zhuo et al., 2001) . As in Mut1, Mut2 (p53 2D, and 2G); to higher-grade anaplastic astrocytomas (grade astrocytomas via PDGFR activation. To refine our understand-III; Figure 2B , 2E, and 2H); to GBMs (grade IV; Figures 2C, 2F , ing of the target cell for p53 inactivation and Ras pathway actiand 2I). As a consequence of germline p53 nullizygosity, these vation in astrocytoma induction, we combined a germline p53 mice also developed lymphomas and sarcomas causing early mutation (Jacks et al., 1994 ) with a neural-specific NF1 mutamortality, likely explaining the reduced development of GBM tion . The resultant mice develop malignant (2/14) ( Figures 2J and 2K ). All Mut3 mice also developed CNS astrocytomas with 100% penetrance and provide evidence for tumors (58/58; Figures 1 and 2K), and among the subset althe cell-of-origin in the subventricular zone (SVZ) of the adult lowed to survive to end-stage of symptoms, approximately brain and a requirement for p53 loss preceding or concomitant 70% had GBMs (14/21; Figure 2K ) exhibiting every discernible inactivation of NF1. The availability of an accurate mouse feature of the human counterpart, including the presence of model for malignant astrocytoma initiation and progression will pseudopalisading tumor cells ( Figures 3A and 3B ), necrosis permit detailed investigation into the pathogenesis of, and ( Figures 3C and 3D ), microvascular proliferation (Figures 3E  novel therapeutic targets for, this incurable tumor. and 3F), and secondary structures of Scherer ( Figures 3G-3J ). All symptomatic Mut3 mice had anaplastic astrocytomas or Results GBMs, while asymptomatic Mut3 mice had either low-grade tumors or no tumors ( Figure 2K and Figure S2 ). Given the Mouse models for malignant astrocytoma 100% incidence of tumor formation, these findings are most In mice, genetic p53 inactivation fails to induce astrocytomas. consistent with a model in which tumors arise as low-grade Instead, the predominant tumors are lymphomas or sarcomas lesions that progress to higher-grade tumors with characteris- (Donehower et al., 1992; Jacks et al., 1994) . We generated tics of GBM over time. three compound mutant mouse strains harboring mutations in In contrast to the two genetic configurations described the linked p53 and NF1 tumor suppressor genes (Mut1-3; Fig- above, the Mut2 strain rarely developed CNS tumors (Figures ure 1). Critical for this purpose was the genetic configuration 1 and 2K; see below). Immunohistochemical analysis showed of a floxed NF1 allele linked to a null p53 allele on mouse chrothat all Mut1 astrocytomas expressed Cre recombinase demmosome 11 (Figure 1 ) and the use of a Cre transgenic strain onstrating NF1 deficiency ( Figure 4A ), while at the molecular under the control of the human glial fibrillary acidic protein prolevel, astrocytomas from the Mut3 mice exhibited inactivation moter (hGFAP-cre) (Malatesta et al., 2003; Zhu et al., submitof both p53 and NF1 genes (Figures 4B and 4C) . These data ted; Zhuo et al., 2001 ). Although GFAP is widely used as a indicate that loss of p53 and NF1 is sufficient to initiate the mature glial-specific marker for normal and reactive astrocytes development of a full spectrum of malignant astrocytomas in in the CNS (Ridet et al., 1997) , more recent data indicate that mice. the human GFAP promoter is also active in most embryonic radial glial cells that exhibit neural progenitor cell properties Molecular validation (Malatesta et al., 2000 (Malatesta et al., , 2003 Noctor et al., 2001; Zhuo et al., Analysis of tumor tissues from human astrocytomas has dem-2001). To determine the scope of hGFAP-cre transgene expresonstrated accrual of specific genetic lesions during prosion and activity, we crossed this mouse strain to the Rosa26-gression from low-grade to high-grade astrocytoma (Holland, 2001; Maher et al., 2001; . These include LacZ reporter strain (Soriano, 1999; Zhuo et al., 2001 ). Be- , n = 20. The incidence of non-CNS tumors observed in Mut1-3 mice is as follows: Mut1, 9/14; Mut2, 4/21; and Mut3, 11/ 58. K: The graph shows astrocytoma frequency and grade observed in end-stage Mut1 mice (n = 14), asymptomatic Mut1* mice (n = 12; 6 to 10 weeks of age), end-stage Mut2 mice (n = 18), end-stage Mut3 mice (n = 21), and asymptomatic Mut3* mice (n = 3; 18 weeks of age). "N," necrosis. Scale bar, 50 m.
deregulation of the Rb-mediated pathway and the PI-3K/AKT/ vide experimental evidence that our tumor models resemble human malignant astrocytoma both at the pathologic and mo-PTEN pathway. We examined expression of two components lecular levels. of the Rb pathway, Cdk4 and cyclin D1, by immunohistochemistry (Figures 5A-5F ; n = 5) and found that these high-grade tumors had intense nuclear expression of both Cdk4 (Figures Site of tumor origin and stem cell characteristics The cell-of-origin of astrocytoma is a much investigated but 5A and 5D) and cyclin D1 proteins ( Figures 5B and 5E ), whereas normal CNS cells did not ( Figure S3 ). To examine the unresolved question. While there has been increasing evidence that human astrocytoma cells resemble neural stem/progenitor status of the Ras pathway, activation of MAP kinase (MAPK) was assessed with phospho-specific antibodies. Consistent cells (Hemmati et al., 2003; Ignatova et al., 2002; Singh et al., 2003) , the existing evidence also supports the model that has with loss of NF1 function, both low-grade ( Figure 5G ) and highgrade astrocytomas ( Figures 5H and 5I ) contain high levels of evoked initial astrocyte dedifferentiation followed by malignant transformation (Bachoo et al., 2002) . Consistent with the canactivated MAPK. In contrast, as in human tumors, activation of AKT was consistently found in higher-grade tumors (grade II, cer stem cell model (Hemmati et al., 2003; Ignatova et al., 2002; Singh et al., 2003 Singh et al., , 2004 , astrocytomas of all grades 0/5, Figure 5J ; grade III, 1/5, Figures 5K and 5L; grade IV, 5/5, Figures 5M and 5P) .
(Mut1, n = 14; Mut3, n = 21) expressed a marker for neural stem cells, nestin Figures S2E and S2F) . In the Two additional noteworthy molecular features of human astrocytoma are present in these mice. VEGF expression inadult brain, two areas have been identified as primary sources of multipotent neural stem cells (Gage, 2000) . One is the SVZ creases in the transition from lower-grade tumors to GBMs ( Figures 5N and 5Q ). In addition, although morphologically simof the lateral ventricle, and the other is the subgranular layer (SGL) in the dentate gyrus of the hippocampus (Alvarez-Buylla ilar, high-grade tumors are molecularly heterogeneous, as evidenced by a regional downregulation of MAPK ( Figure 5O ) Gage, 2000) . Histological analysis of end-stage Mut1 and Mut3 brains showed that, as in human malignant within tumors that retain activated AKT throughout ( Figure 5R ). These data are consistent with a causal role for loss of p53 astrocytoma, high-grade astrocytomas were dispersed throughout the brain ( Figure S4A ), and magnetic resonance imaging and activation of Ras-MAPK in astrocytoma initiation followed by deregulation of the Rb-mediated pathway and the PI-3K/ (MRI) provided radiographic images characteristic of human malignant astrocytoma ( Figure S4B ). To investigate whether tu-AKT/PTEN pathway in progression to GBM. These results pro- B: Genomic DNAs isolated from tail tissues, brain tumors (BT), and hindbrain (HB) of three independent Mut3 mice (#1-#3) were subjected to PCRbased assays for genotyping the NF1 and p53 gene. Upper panel: a PCR assay that identifies the wild-type (WT) and the floxed (flox) NF1 allele mor origin was dispersed or confined to specific regions, we
showed that the tail tissues of the Mut3 mice contained one wild-type NF1
followed a cohort of seven asymptomatic 8-week-old Mut1 allele and one floxed NF1 allele; Cre-expressing tissues (e.g., hindbrain) retained the wild-type NF1 allele but lost most of the floxed allele as a result mice over a 3 week period (the last image was taken when mors were also associated with the SVZ (Figure 6I , inset). We C: Schematic drawing of allelic loss of NF1 and p53 in astrocytoma formation as described in B. The green color is used to label the normal alleles, therefore next examined a cohort of 12 asymptomatic Mut1
including the wild-type allele (+) and the floxed allele (flox); the red color mice at earlier time points between 6 and 10 weeks of age.
is used to label the null alleles, including the recombined floxed allele (⌬)
Seven of the mutant mice showed one or two early lesions per and the knockout allele (−).
brain. Among these seven mutant mice, five showed lesions Adjacent sections from two grade III astrocytomas (GIII) were stained with anti-Cdk4 (A and D), anti-cyclin D1 (B and E), and a marker of proliferation, anti-Ki-67, to identify proliferating cells (C and F). In contrast to normal CNS cells that have little Cdk4 and cyclin D1 expression, highgrade tumors showed strong nuclear staining of Cdk4 and cyclin D1. Adjacent sections from a low-grade astrocytoma (GII) (G and J) and two grade III astrocytomas (GIII) (H and K; I and L) were stained with anti-phospho-erk (P-ERK) and anti-phospho-AKT (P-AKT), respectively. Arrows in G and J point to abnormal tumor cells surrounding neurons; arrows in L indicate P-AKTpositive tumor cells. Sections from a GBM were subjected to double-labeling immunofluorescence with anti-P-AKT (green) and anti-nestin (red) (M and P). "N," necrosis. Sections from a grade III astrocytoma (N) and a GBM (Q) were stained with anti-VEGF. Adjacent sections from a GBM were stained with anti-P-ERK (O) and anti-P-AKT (R). Scale bar, 50 m.
directly associated with the SVZ (Figure 7 ), and the two others different from nestin/GFAP double-positive reactive astrocytes ( Figure 7F , inset) that were identified within the high-grade tuhad a lesion in the hippocampus and the thalamus, respectively, but both contained abnormal cells within the SVZ (data mors. The majority of Ki-67-positive cells expressed nestin (Figures 7H and 7I; 95% ± 2%; n = 96). These observations not shown). Normally, adult neural stem cells are tightly organized in the SVZ ( Figures 7A, 7D , and 7G). In contrast, early are most consistent with the interpretation that SVZ cells are most susceptible to p53/NF1-mediated astrocytoma formation tumor cells were highly infiltrative. Early tumors showed infiltration into the white matter ( Figures 7B, 7E , and 7H) and penetraand that incipient tumor cells share phenotypic characteristics with normal neural stem cells. tion into both the white matter and gray matter ( Figures 7C, 7F , and 7I). Similar to normal neural stem cells ( Figures 7D and 7G , The infiltrative characteristics of malignant astrocytoma typically place the tumor cells within a milieu of nontumor endogearrows) (Doetsch et al., 1999) , early tumor cells also expressed both nestin and GFAP ( Figures 7E and 7F ) and proliferated (Fig- nous neurons and glia. Among a total of 14 GBMs, we analyzed pure noninfiltrative tumor tissues in six GBMs. Two GBMs ures 7H and 7I). These early tumor cells were morphologically Figure 6 . In vivo growth pattern of astrocytomas on the MRI scan A cohort of asymptomatic Mut1 mice was subjected to MRI scan once a week over a 3 week period. Representative T2-weighted images of three Mut1 mice were scanned by MRI at week 1 (Wk1) (A and D) , week 2 (G), and week 3 (Wk3) (B, E, and H) . Following MRI, mice were subjected to histological analysis. Sections at similar levels of MRI images (B, E, and H) were stained with H&E (C, F, and I) . No overt lesions were identified on the images scanned at early weeks (A, D, and G) . Hyperintense T2 signals ranging from strong to moderate to weak were identified on the images at week 3 (B, E, and H). , 2000; Vousden and Lu, 2002) . In contrast, p53 mutations ( Figure 8A ). We also obtained two GBM tumor samples that are among the earliest genetic lesions identified in malignant grew into the ventricular zone from the SVZ ( Figure 8B ). This astrocytomas (Louis et al., 1993; Rasheed et al., 1994 ; van rare direction of growth resulted in pure noninfiltrative tumor Meyel et al., 1994; von Deimling et al., 1992) . The availability tissue. In addition, we analyzed two GBMs that formed multifoof the three Mut strains permitted us to examine whether the cal pseudopalisading tumor cells ( Figure 8C ). The identity of early timing of p53 loss affected tumorigenicity (Figure 1 ). these pure noninfiltrative tumor tissues was further confirmed Whereas the Mut1 strain harbors germline homozygous null by presence of a series of classic neuropathological characterp53 (resulting in p53 loss preceding NF1 loss); the Mut2 strain istics including atypical nuclei. Immunohistochemical analysis harbors a heterozygous germline p53 mutation such that, in revealed that these high-grade tumors contained cells from all the context of hGFAP-cre, NF1 loss is forced by recombination neural lineages. Cells in the pure tumor tissues stained positive and precedes p53 loss of heterozygosity (LOH) in neural profor the following: an astrocytic marker, GFAP ( Figures 8D, 8E , genitors and derivatives. Finally, the Mut3 strain harbors a and 8F); an oligodendrocytic marker, proteolipid protein (PLP), cisNF1flox/p53 mutant chromosome and a wild-type chromothat is the most abundant myelin protein in the mammalian some in CNS cells. LOH in this strain occurs by loss of the CNS (Figures 8G-8I (Singh et al., 1999) . In contrast to the Mut1 and Mut3 strains, the majoral., 2004) has previously been observed in human GBMs. Tuity of Mut2 mice analyzed (17/18) did not develop astrocytomor cells expressed minimal or no myelin basic protein (MBP) mas (Figures 1 and 2K ). About 20% of Mut2 mice survived to ( Figures 8J-8L ), a marker for mature oligodendrocytes. The abthe same age as tumorigenic Mut3 mice but did not develop sence of MBP staining further confirmed that these tumor tisastrocytomas ( Figure 2J ). Approximately 80% of Mut2 mice sues contained minimal or no endogenous neurons or glia, as died at a significantly earlier age compared to Mut3 mice. MBP is normally highly expressed in myelinating oligodendroSince the incidence of non-CNS tumors observed in Mut2 cytes ( Figure 8J , arrows). These data support the model that, in (4/21, 19%) and Mut3 (11/58, 19%) was almost identical, we vivo, glioblastoma cells have the stem cell capacity to undergo cannot attribute the death of Mut2 mice to p53-associated tumultilineage differentiation (Singh et al., 2004) .
mors. We speculate that premature death of Mut2 mice may result from NF1 deficiency in developing CNS cells leading to Early p53 inactivation is critical for malignant abnormal CNS development (Zhu et al., submitted) . To rule out astrocytoma formation the possibility that the premature death may preclude these Genetic mutations in the p53 tumor suppressor gene are common hallmarks of progression in many solid tumors (Vogelstein Mut2 mice from developing astrocytomas, we studied three asymptomatic Mut3 mice at 18 weeks of age, a time point to 45 weeks) mice suggests that these models may resemble primary GBM in humans. Consistently, a recent populationwhen over 85% of Mut2 mice were alive and tumor free ( Figure  2J , arrowhead). Histological analysis revealed that two of three based study reported that p53 mutations were identified in about 28% of human primary GBMs, a subset of which (7.5%) asymptomatic Mut3 mice already exhibited low-grade astrocytomas ( Figure 2K and Figure S2 ). We therefore conclude that also harbored amplification of epidermal growth factor receptor (EGFR) (Ohgaki et al., 2004) . the target cells that give rise to malignant astrocytoma require p53 loss prior to or concomitant to NF1 loss (Ras activation). In the converse configuration, early loss of NF1 fails to provide
The role of the NF1 tumor suppressor gene selective advantage to the target cells for tumor initiation.
in malignant astrocytoma These genetic data demonstrate that the early loss of p53 is Although benign astrocytoma in the optic pathway (optic pathessential for astrocytoma formation in these mouse models.
way glioma) occurs in 15% to 20% of children with NF1, the NF1-associated risk of developing malignant astrocytomas has not been determined until recently. One study using U.S. death Discussion certificates from 1983 to 1997 reported that brain tumors ocMouse models curred 5.5 times more frequently in NF1 patients than in the Detailed molecular characterization of human astrocytoma has general population (Rasmussen et al., 2001) . Particularly, the provided considerable insight into the many oncogenes, tumor relative risk of brain tumors in NF1 patients older than 10 years suppressors, and signaling pathways that become altered in was estimated to reach as much as 100 times greater than the processes of tumor initiation and progression (Holland, those without NF1. Many of the tumors from such patients 2001; Maher et al., 2001; . The present were high-grade malignant astrocytomas (Gutmann et al., study demonstrates that loss of p53 and activation of the Ras 2002) . Furthermore, molecular analysis revealed that NF1-pathway via NF1 inactivation in CNS cells is sufficient to cause associated malignant astrocytomas harbored genetic altermalignant astrocytoma formation with 100% penetrance. Alations, including p53 mutations and p16INK4A/ARF deletions, though malignant astrocytomas of all grades were identified in that are commonly observed in sporadic counterparts (Gutboth Mut1 and Mut3 models, exclusively low-grade lesions mann et al., 2003) . Together, these observations not only prowere found only in presymptomatic mice, except for two Mut1 vide evidence that p53 inactivation can cooperate with NF1 loss in the development of human malignant astrocytomas, but mice with p53-associated lymphomas. As compared to welldifferentiated low-grade astrocytomas in humans, tumors of also suggest that NF1-associated and sporadic malignant astrocytomas may share similar molecular mechanisms unsimilar grade in these models display greater degree of nuclear atypia. Along with these observations, rapid development of derlying tumor progression. Thus, our models may provide a useful tool to dissect the molecular basis of tumor progression GBMs in both Mut1 (from 10 to 20 weeks) and Mut3 (from 20 underlying both NF1-associated and sporadic malignant astroParticularly, p53 mutations and overexpression of PDGFR are often identified in the same tumors, suggesting a cooperative cytomas.
Although one of the first characterized NF1 mutations in soeffect between these two pathways in the development of human malignant astrocytoma (Hermanson et al., 1996) . Furthermatic cells was identified in a sporadic grade III malignant astrocytoma (Li et al., 1992) , loss of NF1 mRNA or protein exmore, the cooperative effect between p53 inactivation and PDGF overexpression has also been established in a mouse pression was not observed in sporadic astrocytomas in a subsequent study using a large number of human primary tumors model using murine retroviral gene transfer (Hesselager et al., 2003) . However, in a recent study using the replication-compeand cell lines (Gutmann et al., 1996) . Thus, it is generally believed that NF1 is not involved in sporadic malignant astrocytotent avian leukemia virus splice acceptor (RCAS)/tv-a system, targeted overexpression of a PDGF ligand (PDGF-B) into nestmas, which instead frequently activate Ras pathways via deregulated PDGFR or EGFR (Holland, 2001; Kleihues and in-and GFAP-expressing tively (Dai et al., 2001) . Furthermore, loss of p53 did not ing neural stem/progenitor cells, glial progenitor cells (e.g., NG2-positive glia), or even terminally differentiated astrocytes, enhance the formation of these PDGF-induced tumors. Possible explanations for the discrepancy between experimentally may serve as a cell-of-origin for malignant astrocytoma. The combination of different glioma-associated genetic lesions may induced tumors via p53/NF1 or PDGF alterations include potentially different cell-of-origin for these tumors, and differinduce different CNS cell types to form malignant astrocytoma. Therefore, our models may mimic a subset of human malignant ences in genetic backgrounds. The present studies demonstrate that the most likely location for the cell-of-origin for astrocytomas with p53 deficiency and activated Ras signaling, which may arise from the SVZ cells. malignant astrocytoma in p53/NF1 mutant mice is in the SVZ of the adult brain (see below). The localization and origin of PDGF-induced tumors arising in neonatal brain cells remains
The timing of genetic mutations We also provide genetic evidence that not only is inactivation unclear. The target cells in that model apparently have greater potential to undergo oligodendrocytic differentiation (Sauvaof both p53 and NF1 sufficient for initiation of astrocytoma formation, but the timing of inactivation is critical. For astrocygeot and Stiles, 2002) . toma induction, p53 inactivation must either precede or coincide with Ras activation via NF1 loss. This is consistent with The site of tumor origin Recent studies indicate that brain tumors, including GBM, conthe observation that mutations in the p53 gene are among the earliest genetic lesions identified in human malignant astrocytain a subpopulation of stem cell-like cells or cancer stem cells that display stem cell characteristics, including self-renewal toma (Holland, 2001; Maher et al., 2001; . In many other solid tumors, including colon cancer and and multipotentiality (Hemmati et al., 2003; Ignatova et al., 2002; Singh et al., 2003 Singh et al., , 2004 , and are responsible for in vivo malignant peripheral sheath tumors (Kinzler and Vogelstein, 1996; , p53 inactivation occurs in later tumor growth (Galli et al., 2004; Singh et al., 2004) . Whether these brain cancer stem cells are derived from neoplastic stages of tumor development when tumor cells already display invasive phenotypes. Thus, either early p53 inactivation protransformation of normal neural stem cells remains to be determined. As compared to previously published mouse models vides a selective advantage for astrocytoma cells to acquire early onset invasive phenotype or activation of Ras signaling for malignant astrocytoma (Ding et al., 2001; Hesselager et al., 2003; Holland et al., 1998 Xiao et al., via NF1 loss leads to apoptosis or senescence of target cells, which can be attenuated by p53 inactivation. 2002), the complete penetrance of the tumor phenotype and rapid tumor development in Mut1 model allowed histological Although activated Ras mutations have not been identified in human malignant astrocytoma, in mice, overexpression of and noninvasive MRI analysis to investigate the site of tumor origin. The results indicate that, as in human GBM, mature tuan activated H-Ras transgene under the control of the hGFAP promoter leads to the development of malignant astrocytomas mors are dispersed throughout the CNS, and yet the earliest identifiable area of a tumor is confined to the SVZ. In the gewith high penetrance (Ding et al., 2001) . This is in striking contrast to the observations that loss of NF1 alone (e.g., Mut2 netic setting of the Mut1 model, all GFAP-positive mature astrocytes or committed glial progenitor cells throughout the mice in this study) is not sufficient to cause astrocytoma formation in the brain (Bajenaru et al., 2002) . Apparently, oncogenic adult brain contain the same genetic mutations (inactivation of both p53 and NF1 tumor suppressors), as do the adult neural Ras signaling is not equivalent to NF1 inactivation. Given that human malignant astrocytoma typically arises during adultstem cells within the SVZ. Therefore, the observation that malignant astrocytomas specifically are located within the SVZ inhood, it is unlikely that human patients contain a significant number of developing CNS cells with high levels of Ras signaldicates that (1) there exists a specific cell type(s) in the SVZ that is more susceptible to p53/NF1-mediated astrocytoma ing as the Ras transgenic model does. In contrast, mutant cells with p53/NF1 deficiency via co-LOH in the Mut3 model most formation as compared to those in other regions of the brain, or (2) the microenvironment in the SVZ provides a favorable likely arise during adulthood, as these mutant mice had normal development and did not develop tumors until 5 months of niche for the growth of early tumor cells, which either arise within the SVZ or migrate there from the other regions of the age. In this regard, the Mut3 mutant mice may provide a better model that mimics human malignant astrocytoma as an adult brain. Based upon current knowledge, one fundamental difference between the SVZ and the other regions of the adult brain disease compared to the Ras transgenic mice. (except for the SGL of the hippocampal dentate gyrus) is the existence of specific GFAP-positive "astrocyte"-like cells, Clinical implication Our study cannot rule out alternative models for astrocytoma which possess the capacity of stem cells to undergo selfrenewal and multilineage differentiation (Alvarez-Buylla et al., initiation such as cellular dedifferentiation and transformation (Bachoo et al., 2002; Galli et al., 2004; Singh et al., 2004) . The 2001; Gage, 2000; Temple and Alvarez-Buylla, 1999) . It has been shown that these GFAP-positive neural stem cells are expression of nestin and other lineage-specific markers in tumor cells can simply reflect deregulated gene expression. present in the SVZ of both human and rodent adult brains (Doetsch et al., 1999; Sanai et al., 2004) . In light of these obserWhether these nestin-expressing cells within tumors represent the cancer stem cells remains to be determined. Nevertheless, vations, our results suggest that the GFAP-positive neural stem cells in the SVZ of the adult brain are a likely candidate to be identification of the SVZ as the site of tumor origin in our models may have implications on therapeutic strategies for prethe cell-of-origin for malignant astrocytomas in our models.
A recent study demonstrated that neonatal astrocytes may venting and treating a subset of human malignant astrocytomas (Recht et al., 2003) . These observations challenge models serve as a cell-of-origin for malignant astrocytoma in response to deregulated EGFR signaling and INK4a/ARF deficiency.
of gliomagenesis, which assume tumor development from at large transformed glia or committed glial progenitors. As a conThus, it is possible that different cell types in the CNS, includ-ments were performed using a 4.7 T horizontal magnet equipped with a sequence, for a tumor that arises from the SVZ, current treatVarian Inova imaging system. The mouse was placed in a home-built eightment focusing merely on local lesions will not be sufficient to element birdcage coil (w2 cm in diameter). Fast scout images in a sagittal eradicate tumor cells, as these cells may be eventually replenorientation indicated pertinent slices for high-resolution images. T1-ished from the cell pool within the SVZ. This may offer one weighted (TR = 250 ms; TE = 15 ms) and T2-weighted (TR = 1500 ms; TE = explanation of why the current treatment for malignant astrocy-80 ms) spin echo multislice (SEMS) axial images were acquired, and contoma ultimately fails.
trast-enhanced T1-weighted images were acquired immediately after i.v. bolus injection of Gd-DTPA-BMA (0.1 mmol/kg body weight; Omniscan).
Experimental procedures
MRI parameters included a field of view (FOV) of 3-4 cm, a matrix size of 128 × 128, a slice thickness of 1 mm, and two acquisitions. Following MRI, Generation of Mut1-3 mutant mice the mouse was sacrificed, and a whole mouse brain was dissected and was subjected to histological analysis, as described above. Follow-up study The mutant mice harboring the linked p53 null mutation and the floxed NF1 examined asymptomatic mutant mice once a week over a 3 week period to allele on the same chromosome (cis mice) were generated by crossing detect tumor development. NF1 flox/+ mice to p53 +/− mice to generate p53
+/−
;NF1 flox/+ trans mice that were then crossed to wild-type F1 129Svj/C57Bl6 mice (Jacks et al., 1994; P20 Pre-ICMIC grant CA86354. Mice were aged until signs of distress appeared. Then, mice were perfused with 4% paraformaldehyde (PFA), and brains were dissected, followed by overnight postfixation in 4% PFA at 4°C. Brains were divided into three pieces along the rostral to caudal axis, and each piece was processed for (Kleihues and Cavenee, 2000) . Adjacent sections were subjected to immunohistochemistry (see below). For PCR analysis, tumor Alvarez-Buylla, A., Garcia-Verdugo, J.M., and Tramontin, A.D. (2001) . A unitissues were dissected in ice-cold PBS and digested with proteinase K as fied hypothesis on the lineage of neural stem cells. Nat. Rev. Neurosci. 2, described . 287-293.
Immunohistochemistry Bachoo, R.M., Maher, E.A., Ligon, K.L., Sharpless, N.E., Chan, S.S., You, Paraffin sections were deparaffinized and rehydrated. Sections were sub-M.J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R., et al. (2002) . Epiderjected to immunohistochemistry as described previously (Zhu et al., 1998 , mal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to 2001). The visualization of primary antibodies was performed with either a astrocyte axis. Cancer Cell 1, 269-277. horseradish peroxidase system (Vectastain ABC kit, Vector) or immunofluorescence by using Cy3-conjugated anti-rabbit/mouse and Cy2-conjugated Bajenaru, M.L., Zhu, Y., Hedrick, N.M., Donahoe, J., Parada, L.F., and Gutanti-mouse/rabbit secondary antibodies (Jackson lab) at 1:200 dilution. The mann, D.H. (2002) . Astrocyte-specific inactivation of the neurofibromatosis dilutions of primary antibodies used in this study were as follows: GFAP 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 22, (rabbit, 1:2000, DAKO), nestin (mouse, 1:200, Chemicon), Cre (mouse, 5100-5113. 1:1000, BABCO), P-ERK (rabbit, 1:200, Cell Signaling), P-AKT (rabbit, Cichowski, K., and Jacks, T. (2001) . NF1 tumor suppressor gene function: 1:100, Cell Signaling), Cdk4 (rabbit, 1:200, Santa Cruz), cyclin D1 (mouse, narrowing the GAP. Cell 104, 593-604. 1:200, Zymed), Ki-67 (rabbit, 1:1000, Novocastra), VEGF (mouse, 1:50, Upstate Biotech), Olg2 (rabbit, 1:300, a gift of Dr. R. Lu), NeuN (mouse, 1:500, Cichowski, K., Shih, T.S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, Chemicon), Tuj1 (mouse, 1:200, Covance), NF200 (rabbit, 1:200, Sigma).
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